RASopathy Gene Mutations in Melanoma

Slides:



Advertisements
Similar presentations
Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome Phenotype  Claudio Carta, Francesca Pantaleoni, Gianfranco.
Advertisements

Is NF-κB2/p100 a direct activator of programmed cell death?
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC  Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,
Grouping of Multiple-Lentigines/LEOPARD and Noonan Syndromes on the PTPN11 Gene  Maria Cristina Digilio, Emanuela Conti, Anna Sarkozy, Rita Mingarelli,
Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms  Jerald Z. Gong, James R. Cook, Timothy.
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells  Christian Posch,
Jack L. Arbiser, Michael Y. Bonner 
Wanlong Ma, Hagop Kantarjian, Xi Zhang, Chen-Hsiung Yeh, Zhong J
Volume 113, Issue 3, Pages (May 2003)
Mechanisms of mast cell signaling in anaphylaxis
Figure 1 Therapeutic targeting of the B-cell receptor (BCR)
The function of PTB domain proteins
Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma
Targeted Therapies in Melanoma: Translational Research at Its Finest
Pedram Gerami, Amy S. Paller  Journal of Investigative Dermatology 
HOPX: The Unusual Homeodomain-Containing Protein
Phoxy Lipids Cell Volume 105, Issue 7, Pages (June 2001)
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Michael L. Frisoli, John E. Harris 
Ha Linh Vu, Sheera Rosenbaum, Claudia Capparelli, Timothy J
Takashi Hashimoto, Norito Ishii, Daisuke Tsuruta 
WW domains Structure Volume 4, Issue 5, Pages (May 1996)
Clinical Snippets Journal of Investigative Dermatology
Opioids and neovascularization; pro or anti?
TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention  Karsten Mahnke, Alexander H. Enk  Journal.
Melanoma: New Insights and New Therapies
Efrat Avigad Laron, Emil Aamar, David Enshell-Seijffers 
BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Volume 117, Issue 3, Pages (September 1999)
Searching for the Chokehold of NRAS Mutant Melanoma
Structure of the TPR Domain of p67phox in Complex with Rac·GTP
Capillary Malformation–Arteriovenous Malformation, a New Clinical and Genetic Disorder Caused by RASA1 Mutations  Iiro Eerola, Laurence M. Boon, John.
Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
NRAS, NRAS, Which Mutation Is Fairest of Them All?
Shyam S. Jayaraman, David J. Rayhan, Salar Hazany, Michael S. Kolodney 
Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome 
Protein Tyrosine Phosphatases in the Human Genome
Global Patterns of Methylation in Sézary Syndrome Provide Insight into the Role of Epigenetics in Cutaneous T-Cell Lymphoma  Sean Whittaker  Journal of.
Signaling Interplay in Ras Superfamily Function
Cedric Badowski, Adelene Y. L
Kwang S. Suh, Michihiro Mutoh, Michael Gerdes, Stuart H. Yuspa 
Mutations in the Lipase H Gene Underlie Autosomal Recessive Woolly Hair/Hypotrichosis  Yutaka Shimomura, Muhammad Wajid, Lynn Petukhova, Lawrence Shapiro,
RAS Proteins and Their Regulators in Human Disease
The Ras-Byr2RBD Complex
Zika Virus Infection RIG-ged by Keratinocytes and Fibroblasts
AKT/PKB Signaling: Navigating the Network
Fig. 4 Effect of LRRK2 mutations on protein kinase activity and GTPase activity. Effect of LRRK2 mutations on protein kinase activity and GTPase activity.
Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01  Zhenhua Yue, Yonghu Sun, Chuan.
More Than Many: How to Manage the Most Frequent Cancer?
Cancer Stem Cells in Squamous Cell Carcinoma
Splice-Site Mutation of Exon 3 Deletion in the Gamma-Glutamyl Carboxylase Gene Causes Inactivation of the Enzyme  Da-Yun Jin, Cees Vermeer, Darrel W.
Crystal Structure of a Phosphoinositide Phosphatase, MTMR2
Newly Discovered Olfactory Receptors in Epidermal Keratinocytes Are Associated with Proliferation, Migration, and Re-Epithelialization of Keratinocytes 
Journal of Investigative Dermatology
Volume 92, Issue 3, Pages (February 1998)
Erratum Journal of Investigative Dermatology
Binding Affinity and Interaction of LL-37 with HLA-C
Yoav Gilad, Carlos D. Bustamante, Doron Lancet, Svante Pääbo 
NF1 Tumor Suppressor Gene Function
Platelet-derived growth factor (PDGF) signalling pathway.
Journal of Investigative Dermatology
Understanding Fragile X Syndrome
Journal of Investigative Dermatology
Epidermolysis Bullosa: The Expanding Mutation Database
Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing  Richard A.F. Clark,
Guilty as charged Cancer Cell
Just the Beginning: Novel Functions for Angiotensin-Converting Enzymes
Brief Review – Growth Factors and Receptors
Pleckstrin Homology Domains: Two Halves Make a Hole?
Volume 95, Issue 2, Pages (October 1998)
Presentation transcript:

RASopathy Gene Mutations in Melanoma Ruth Halaban, Michael Krauthammer  Journal of Investigative Dermatology  Volume 136, Issue 9, Pages 1755-1759 (September 2016) DOI: 10.1016/j.jid.2016.05.095 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Mitogen-activated protein kinase pathway indicating RASopathy mutant genes and those shared with melanoma. The green and yellow bars are RASopathy genes with (presumably) activating and inactivating mutations, respectively. Those with amino acid changes shared with melanoma are marked with a red dot. CFCS, cardio-facio-cutaneous syndrome; GDP, guanosine diphosphate; GTP, guanosine triphosphate Noonan-LS, Noonan-like syndrome; RTK, receptor tyrosine kinase. Journal of Investigative Dermatology 2016 136, 1755-1759DOI: (10.1016/j.jid.2016.05.095) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Schematic representation of RASA2 and PTPN11 mutations in melanomas and RASopathies. (a) RASA2. (b) PTPN11. The mutations indicated above and below the bar are those identified in melanoma and those shared with RASopathy syndromes, respectively. In blue are mutations shared with other cancers. The bars indicate conserved domains. Numbers below the bars indicate the amino acid positions. BTK, Bruton’s tyrosine kinase Cys-rich motif; C2, protein kinase C conserved region 2; LP, LEOPARD syndrome; LS, Legius syndrome; NS, Noonan syndrome; PH, pleckstrin homology-like domain; RAS-GAP, GTPase-activator protein for Ras-like GTPases; SB, substrate binding site; SH2, Src homology 2 domain. Journal of Investigative Dermatology 2016 136, 1755-1759DOI: (10.1016/j.jid.2016.05.095) Copyright © 2016 The Authors Terms and Conditions